RAS-targeted therapies: is the undruggable drugged?
AR Moore, SC Rosenberg, F McCormick… - Nature reviews Drug …, 2020 - nature.com
Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity
Mitogen-activated protein kinase (MAPK) pathways represent ubiquitous signal transduction
pathways that regulate all aspects of life and are frequently altered in disease. Here, we …
pathways that regulate all aspects of life and are frequently altered in disease. Here, we …
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
ME Bahar, HJ Kim, DR Kim - Signal transduction and targeted therapy, 2023 - nature.com
Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …
underscores the urgent need for enhanced insights into the molecular and cellular …
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
It is well established that multifactorial drug resistance hinders successful cancer treatment.
Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial …
Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial …
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
V Subbiah, RJ Kreitman, ZA Wainberg… - Journal of Clinical …, 2018 - ascopubs.org
Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib
(MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a …
(MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a …
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …
[HTML][HTML] Clinical development of BRAF plus MEK inhibitor combinations
V Subbiah, C Baik, JM Kirkwood - Trends in cancer, 2020 - cell.com
Genomic profiling shows that many solid tumors are characterized by specific driver
aberrations, and this has expanded the therapeutic options for many patients. The mitogen …
aberrations, and this has expanded the therapeutic options for many patients. The mitogen …
Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments
Molecular alterations in cancer genes and associated signaling pathways are used to inform
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …
Targeted therapy in melanoma and mechanisms of resistance
The common mutation BRAFV600 in primary melanomas activates the mitogen-activated
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …
Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies
Aneuploidy is a ubiquitous feature of human tumors, but the acquisition of aneuploidy
typically antagonizes cellular fitness. To investigate how aneuploidy could contribute to …
typically antagonizes cellular fitness. To investigate how aneuploidy could contribute to …